v3.25.1
Segment
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Segment Segment
The Company reports segment information in accordance with the management approach, which reflects the internal reporting utilized by the Chief Operating Decision Maker (“CODM”), the Company’s President and Chief Executive Officer. Based on the information used by the CODM to allocate resources and assess the Company’s performance, the Company has determined it operates in one segment. The CODM reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance.
The CODM evaluates the performance of the Company’s sole reportable segment based on net income or loss that also is reported on the condensed consolidated statements of operations and comprehensive loss as net income or loss. The measure of segment assets is reported on the condensed consolidated balance sheets as total assets.
Three Months Ended
March 31,
20252024
Revenue$7 $3 
Operating expenses:
  Research and development
Technical operations21,833 17,271 
Clinical development
8,919 8,383 
Non-clinical research
5,146 10,528 
Facilities and technology7,549 6,992 
  Total research and development expenses43,447 43,174 
  General and administrative
Business support9,071 8,916 
Corporate expenses and outside services3,831 3,668 
Facilities and technology1,144 910 
  Total general and administrative expenses14,046 13,494 
Other operating income, net(119)(1,090)
Total operating expenses57,374 55,578 
Loss from operations(57,367)(55,575)
Interest income, net3,862 6,819 
Other income, net1,310 1,090 
Impairment of other investments— (13,001)
Total other income, net5,172 (5,092)
Net loss$(52,195)$(60,667)
Total expenditures for additions to the Company’s property and equipment, net were $0.3 million and $0.2 million for the three months ended March 31, 2025 and 2024, respectively.